Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
What executive actions and regulatory changes on prescription drug pricing did President Donald Trump announce between 2018 and 2020?
Executive Summary
President Trump announced a series of executive actions and regulatory proposals between 2018 and 2020 aimed at lowering prescription drug costs through four headline executive orders and an earlier 2018 policy "blueprint" that set regulatory priorities: encouraging importation, redirecting rebates to patients to curb middlemen profits, expanding access to insulin and epinephrine through 340B-type mechanisms, and advancing international price benchmarking or indexation for Medicare drug payments. These measures combined public messaging, emergency and administrative orders, and regulatory rulemaking directives to HHS and CMS, producing a mix of finalized, stayed, and litigated actions with divergent reactions from industry, patient groups, and states [1] [2] [3] [4] [5] [6].
1. A bold blueprint — Trump’s 2018 playbook to reshape drug pricing
The 2018 White House blueprint framed the administration’s longer-term agenda by targeting perceived “foreign freeloading,” encouraging competition from generics and biosimilars, and promising regulatory fixes to reduce gaming of patents and rebates, while also proposing changes to Medicare Part D benefit design such as more flexibility for plan sponsors and pilot ideas like free generics for low-income seniors. The document directed the Department of Health and Human Services to pursue a mix of rulemaking and enforcement actions rather than a single legislative fix, signaling an executive-led approach to drug prices if Congress did not act. The blueprint set the terms for later executive orders and regulatory moves by emphasizing innovation plus competition as the administration’s primary levers [2].
2. Four executive orders in 2020 — promises, targets, and legal friction
Between July 24 and late July 2020, the President signed four executive orders intended to lower out-of-pocket costs and restructure incentives: one on allowing states to import certain prescription drugs, one seeking to eliminate rebates that benefit pharmacy benefit managers (PBMs) and instead flow savings to patients, one aimed at expanding access to insulin and injectable epinephrine through federal 340B-like mechanisms, and one linking Medicare Part B prices to international benchmarks or pursuing a Most Favored Nation approach. The orders were framed as immediate steps to protect patients, but they relied heavily on HHS and CMS rulemaking and faced near-immediate legal and implementation challenges. The executive orders were policy signals with complex operational hurdles, not turnkey reforms [1] [4] [5].
3. Rebates and “kickbacks to middlemen” — policy detail and controversy
A central executive action—Executive Order 13939—targeted rebates and what the administration called “kickbacks” to PBMs, directing HHS to pursue regulations to have rebates benefit patients at the point of sale and to strip safe-harbor protection from certain retrospective price concessions. Proponents argued this would lower out-of-pocket costs for patients purchasing drugs by preventing list-price inflation obscured by post-sale rebates. Opponents — including PBMs, insurers, and some provider groups — warned that removing rebate structures without alternative mechanisms could raise premiums and disrupt negotiated discounts, and several of the related regulatory efforts were subject to legal challenge and administrative pauses. Rebate reform was framed as pro-patient but operationally contested [3] [6].
4. Importation and international price benchmarking — promises vs. execution
The administration pursued two international strategies: easing importation rules for state-run programs and pursuing international reference pricing for Medicare Part B drugs. Importation proposals raised safety and supply-chain questions, even as supporters emphasized lower prices in Canada and other countries. The Most Favored Nation or international price index proposals sought to cap Medicare payments based on lower foreign prices for certain drugs—an aggressive shift from U.S.-only market pricing that drew immediate legal scrutiny and implementation obstacles. Both approaches promised lower prices but depended on complex cross-border and global-market mechanics and encountered practical, regulatory, and judicial resistance [1] [5] [6].
5. Mixed results and divergent reactions — what actually changed by 2020
By the end of 2020 the administration had announced and initiated multiple regulatory tracks and model pilots — for example, the Part D Senior Savings Model and insulin-access initiatives — but many of the headline changes remained incomplete, stayed, or contested in court. Industry groups and patient advocates split: some praised the focus on patient out-of-pocket costs and competition, while others warned of destabilizing negotiated rebate systems and unintended premium effects. The overall record shows a strategy relying on executive tools and agency action rather than congressional statute, producing concrete pilot programs and rulemaking efforts but limited across-the-board, durable reform within the 2018–2020 window [1] [2] [4] [6].